GENEO Capital Entrepreneur is helping i-Run, the French leader in the sale of running, trail, outdoor, fitness and athletic products, to reorganize its capital in order to support its managerial transition and accelerate its development projects in France and Europe.
GENEO Capital Entrepreneur supports ENYGEA's growth by making its first mezzanine investment
GENEO Capital Entrepreneur is helping i-Run, the French leader in the sale of running, trail, outdoor, fitness and athletic products, to reorganize its capital in order to support its managerial transition and accelerate its development projects in France and Europe.
GENEO Capital brings together a group of long-term investors to support i-Run in its growth and capital reorganization.
GENEO Capital Entrepreneur is helping i-Run, the French leader in the sale of running, trail, outdoor, fitness and athletic products, to reorganize its capital in order to support its managerial transition and accelerate its development projects in France and Europe.
G.A.C Group is reorganising its capital around its management team, with the support of GENEO Capital Entrepreneur, its historical founder and Bpifrance.
The Executive Committee of Safic-Alcan, together with its existing private equity partners EMZ partners, Sagard and Société Générale Capital Partenaires, are pleased to announce the start of their next project.
GENEO Capital Entrepreneur is pleased to support the management of Safic Alcan in its new growth phase
The Executive Committee of Safic-Alcan, together with its existing private equity partners EMZ partners, Sagard and Société Générale Capital Partenaires, are pleased to announce the start of their next project.
GENEO Capital Entrepreneur becomes the new reference shareholder of the Zurflüh-Feller Group
Paris, June 21, 2022 - The Zurflüh-Feller Group, the French leader and a major player in Europe in the manufacture of components for roller shutters, is leaving the fold of the industrial holding company Edify to welcome a pool of evergreen investors led by GENEO Capital Entrepreneur alongside the management team headed by Thierry Jeanmart. This transaction is part of a long-term positive impact investment approach.
GENEO Capital Entrepreneur supports the development of Neftys Pharma alongside UI Investissement and Crédit Agricole Centre France to accelerate the consolidation of the European market for the distribution of veterinary products
GENEO Capital Entrepreneur, UI Investissement and Crédit Agricole Centre France are joining forces to support the very strong development of Neftys Pharma. This investment marks the opening of a new phase in the group's growth by giving it the means to lead the consolidation of the European market.
GENEO Capital Entrepreneur supports the growth and CSR strategy of the Odigo group via Relance Bonds
GENEO Capital Entrepreneur announces the setting up of Relance Bonds, within the framework of the programme subscribed by insurers and partially guaranteed by the State.
Odigo is an international player in the publishing of Contact Center as-a-Service (CCaS) cloud software solutions that manage conversations between consumers/citizens and brands. Thanks to this long-term financing, Odigo intends to continue deploying its growth strategy, while strengthening its employer brand and human capital.
GENEO launches a quasi-equity fund to help small and medium-sized companies transform themselves to prepare for tomorrow's world
The GENEO Mezzanine positive impact fund is designed to finance small and medium-sized companies in the form of quasi-equity (mezzanine). Unique in its approach, this fund aims not only to finance the growth of companies, but also to support them intensively in their innovation programme for positive impact, through a tailor-made coaching programme and significant financial incentives.
GENEO publishes its first impact report
This first impact report is an opportunity for GENEO to present its unique approach to positive impact as an investor. Rationale, commitments, organisation, support for invested companies, investment process and endowment funds: find out how we operate and what progress we have made in this area in 2021.